BNGO_OUT_1 [2025-04-01 16:51:37 -0400] 2044 Bytes | 599 tokens | Cum: 599 tkns (7.49% of 8k)
==========================================================================

Listen up, partner—it's 4:51:36 PM on Tue Apr 01, 2025 -0400, and I’m revved up about Bionano Genomics (BNGO), climbing from 2.79 to 3.19. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Bionano Genomics:

C1 - Today 12:26PM - Q4 2024 Bionano Genomics Inc Earnings Call
C2 - 03:04AM - Bionano Genomics Inc (BNGO) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and ...
C3 - Mar-31-25 08:30PM - Bionano Genomics (BNGO) Q4 2024 Earnings Call Transcript
C4 - Mar-31-25 08:30PM 08:11PM - Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
C5 - Mar-31-25 08:30PM 04:01PM - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
C6 - Mar-24-25 08:00AM - Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
C7 - Mar-18-25 08:00AM - Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
C8 - Mar-14-25 08:00AM - Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Bionano Genomics (BNGO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BNGO_OUT_3 [2025-04-01 16:51:41 -0400] 1101 Bytes | 322 tokens | Cum: 923 tkns (11.54% of 8k)
==========================================================================

Showing C5 (chunk 1 of 14): C5:
**Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025**
Date: Mar-31-25 08:30PM 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052748/0/en/Bionano-Reports-Fourth-Quarter-and-Full-Year-2024-Results-and-Provides-Revenue-Outlook-for-2025.html

March 31, 2025 16:01 ET| Source:Bionano GenomicsBionano Genomics

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025.

“2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of transforming the way the world sees the genome an

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_5 [2025-04-01 16:51:41 -0400] 939 Bytes | 279 tokens | Cum: 1279 tkns (15.99% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T00:30:14Z - Bionano Genomics (BNGO) Q4 2024 Earnings Call Transcript...
A2 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A3 - 2025-03-31T20:15:14Z - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025...
A4 - 2025-03-31T20:01:00Z - Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 - Bi...
A5 - 2025-03-31T14:00:19Z - Here are the major earnings after the close today...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BNGO_OUT_7 [2025-04-01 16:51:44 -0400] 321 Bytes | 94 tokens | Cum: 1375 tkns (17.19% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1):

[INFO] Your document request exceeded 20000 characters. If you need more, please request additional documents separately.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_9 [2025-04-01 16:51:44 -0400] 925 Bytes | 297 tokens | Cum: 1713 tkns (21.41% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-03T19:34:00Z - Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
B2 - 2024-12-31T20:26:00Z - Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
B3 - 2024-10-10T12:00:00Z - Bionano Announces Preliminary 3Q 2024 Revenues and Cash
B4 - 2024-07-17T17:35:17Z - 10 Consumer Discretionary Stocks With Whale Alerts In Today's Session - Benzinga
B5 - 2024-05-08T22:30:14Z - Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript
B6 - 2024-05-08T20:01:00Z - Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BNGO_OUT_11 [2025-04-01 16:51:46 -0400] 733 Bytes | 202 tokens | Cum: 1917 tkns (23.96% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/03/3004131/0/en/Bionano-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.htmlBionano Genomics announced a $10 million registered direct offering, with the proceeds to be used for general corporate purposes. The offering includes the sale of common stock and warrants to institutional investors.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_13 [2025-04-01 16:51:47 -0400] 1095 Bytes | 296 tokens | Cum: 2255 tkns (28.19% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements and the related notes i...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Bionano Genomics, Inc. (the Company) issued a press release announcing certain performance results for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is...

S8 - 2025-02-21 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 4, 2025, Bionano Genomics, Inc. (the Company) suspended, and ceased offering any shares of its common stock, par value $0.0001 per share, (the Common Stock) pursuant to the prospectus supplement dated May 10, 2023...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BNGO_OUT_15 [2025-04-01 16:51:50 -0400] 1098 Bytes | 232 tokens | Cum: 2489 tkns (31.11% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements and the related notes included elsewhere in this Annual Report. All dollar amounts and share counts presented below have been rounded to the nearest thousand and, thus are approximate. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the risks described in Part I, Item 1A Risk Factors and elsewhere in this Annual Report.

Overview

We are a provider of genome analysis so

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BNGO_OUT_17 [2025-04-01 16:52:01 -0400] 6407 Bytes | 1839 tokens | Cum: 4330 tkns (54.12% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 133,268 | Perf Month: -22.50% | Option/Short: No / Yes | Sales Y/Y TTM: -0.82% |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 206.56K | Perf Quarter: -75.40% | Short Float: 18.68% | ROE: -161.77% |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.65 | Index: - | Short Ratio: 2.46 | ROI: -250.76% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 31.26 | Market Cap: 8.47M | Short Interest: 0.51M | Sales Surprise: 36.05% |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.35 | Shs Outstand: 2.73M | Beta: 2.09 | EPS Surprise: 0.00% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -9.10% | Shs Float: 2.72M | Sales Q/Q: -34.83% | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -35.32% | Inst Own: 10.23% | Sales past 5Y: 44.98% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -84.40% | Insider Own: 0.36% | Employees: - | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: -6.06% | Insider Trans: 0.00% | Debt/Eq: 0.46 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Bionano Genomics, Inc. (BNGO) by Chaubey Alka (Chief Medical Officer) on 2025-03-14
- Stock Option (Right to Buy): 6966 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by OLDAKOWSKI MARK (Chief Operating Officer) on 2025-03-14
- Stock Option (Right to Buy): 6966 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Holmlin R. Erik (President and CEO) on 2025-03-14
- Common Stock: 198 shares at $3.47 (D) Footnote: The reporting person is reporting the withholding by the Issuer of an aggregate of 198 shares of common stock in connection with shares that vested on March 14, 2025 pursuant to an PSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the PSU award.
- Stock Option (Right to Buy): 17449 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Adamchak Mark (Principal Accounting Officer) on 2025-03-14
- Stock Option (Right to Buy): 3029 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Dixon Jonathan V. (General Counsel) on 2025-03-14
- Stock Option (Right to Buy): 6559 shares at $0 (D)

Inside Trans: Bionano Genomics, Inc. (BNGO) by Adamchak Mark (Principal Accounting Officer) on 2025-02-15
- Common Stock: 4 shares at $5.73 (D) Footnote: The reporting person is reporting the withholding by the Issuer of an aggregate of 4 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

Inside Trans: Bionano Genomics, Inc. (BNGO) by Chaubey Alka (Chief Medical Officer) on 2025-02-15
- Common Stock: 18 shares at $5.73 (D) Footnote: The reporting person is reporting the withholding by the Issuer of an aggregate of 18 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 36579000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -204103000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.1
Average Volume: 89229.36
30-Day High: 4.1
30-Day Low: 2.79

[Detailed Financials: Q2 2024]
- Total Assets: $129,364,000.0
- Total Liabilities: $49,027,000.0
- Total Equity: $80,337,000.0
- Current Assets: $60,568,000.0
- Current Liabilities: $37,175,000.0

[Income Statement: Q2 2024]
- Revenue: $7,771,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.24

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,674,000.0

[Detailed Financials: Q1 2024]
- Total Assets: $157,995,000.0
- Total Liabilities: $75,224,000.0
- Total Equity: $82,771,000.0
- Current Assets: $85,611,000.0
- Current Liabilities: $58,506,000.0

[Income Statement: Q1 2024]
- Revenue: $8,769,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.6

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $-2,189,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BNGO_OUT_19 [2025-04-01 16:52:04 -0400] 676 Bytes | 167 tokens | Cum: 4827 tkns (60.34% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BNGO_IN_21 [2025-04-01 16:52:05 -0400] 126 Bytes | 29 tokens | Cum: 4925 tkns (61.56% of 8k)
==========================================================================

====================================
[2025-04-01 16:52:05] # Analysis Completed
Elapsed Time: 28.48 seconds